# A Study Comparing the Efficacy of Pataday® Once Daily Relief Extra Strength to Claritin® Tablets 24-Hour in Subjects With Allergic Conjunctivitis

> **NCT05265910** · PHASE4 · COMPLETED · sponsor: **Andover Research Eye Institute** · enrollment: 58 (actual)

## Conditions studied

- Allergic Conjunctivitis

## Interventions

- **DRUG:** olopatadine hydrochloride ophthalmic solution 0.7%
- **DRUG:** loratadine 10 mg
- **DRUG:** Tears Naturale
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05265910
- **Lead sponsor:** Andover Research Eye Institute
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-12-14
- **Primary completion:** 2022-04-23
- **Final completion:** 2022-04-23
- **Target enrollment:** 58 (ACTUAL)
- **Last updated:** 2022-05-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05265910

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05265910, "A Study Comparing the Efficacy of Pataday® Once Daily Relief Extra Strength to Claritin® Tablets 24-Hour in Subjects With Allergic Conjunctivitis". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05265910. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*